WHO Guideline Update Recommends Against 2 COVID-19 Monoclonal Treatments
September 26, 2022

WHO: Evidence is lacking for clinical effectiveness of Xevudy and Regen-Cov against the COVID-19 variants that are currently circulating.

Phase 3 Trial Now Underway of Investigational mRNA-based Influenza Vaccine
September 20, 2022

Pfizer announced that the first participants have been dosed in a novel phase 3 efficacy clinical trial of its quadrivalent modified RNA influenza vaccine candidate.

Study: At-home COVID-19 Tests Less Effective After Omicron Emergence
September 19, 2022

The performance of 3 commercially available COVID-19 home-testing kits worsened during the emergence of the omicron variant, according to a new cross-sectional study.

COVID-19 Bivalent Booster Shot Q&A for Clinicians
September 09, 2022

Get answers to 7 questions you may have regarding bivalent booster dose vaccination for patients from the US Centers for Disease Control and Prevention.

The Future of US Antimicrobial Resistance is in Our Hands and There is Work to Do
August 31, 2022

Steer clear of antibiotic Rxs whenever possible, says Anne Meneghetti, MD, to help the US get back to pre-COVID levels of antimicrobial stewardship.

Primary Care Can Help Restore US Antibiotic Stewardship, Starting with Flu Shots
August 30, 2022

Preventing viral infections with vaccination can keep the most vulnerable out of the hospital, reducing the risk of bacterial superinfections.

Superinfection Rate in Hospitalized COVID-19 Patients was Found to be Low
August 29, 2022

Only 9% of inpatients with COVID-19 had a bacterial superinfection that could be treated with antibiotics which curbed use of broad-spectrum antimicrobials.

Pfizer Reports Positive Topline Phase 3 Data for Bivalent RSV Vaccine in Older Adults
August 26, 2022

Pfizer announced that a single dose of the vaccine, RSVpreF, demonstrated 85.7% efficacy against severe disease, defined by ≥3 symptoms.

Antimicrobial Resistance During COVID-19 Gained New Ground: Expert Perspective
August 26, 2022

Widespread antibiotic prescribing in the first year of the pandemic set back US progress on the fight against antimicrobial resistance, says Anne Meneghetti, MD.

New Real-world Study Finds Average Length of COVID-19 Infectiousness is 5 Days
August 19, 2022

A new real-world study found that two-thirds of patients with COVID-19 were still infectious 5 days and one-fourth at 7 days after symptom onset.